- 4basebio
- 03 March 2026 16:31:41
Source: Sharecast
Wolosin, who joined the company in September as vice-president of business development, would now lead 4basebio’s global commercial strategy, business development initiatives and customer engagement, as it scaled its synthetic DNA platform across the cell and gene therapy, mRNA and vaccine markets.
Her promotion followed the recent appointment of Dr Amy Walker as chief executive, succeeding Dr Heikki Lanckriet.
The firm said Wolosin has more than 25 years of life sciences experience, including senior commercial roles at Emmes, TriLink BioTechnologies and Thermo Fisher Scientific.
At Emmes, she led the buildout of the North America commercial organisation to support growth in biopharma innovator trials and later-phase studies.
At Thermo Fisher Scientific, she oversaw go-to-market launches for advanced therapy offerings, including the expansion of viral vector manufacturing at the group’s Plainville, Massachusetts facility.
“4basebio is moving into an accelerated commercial phase as the company scales operations and builds partnerships across RNA, cell and gene therapy and vaccine development,” said chief executive Amy Walker.
“Since joining 4basebio, Christine has demonstrated an ability to build strategic relationships within the nucleic acid manufacturing space and a deep understanding of customer needs in the advanced therapy sector.
“Her leadership and experience will be instrumental as we work to establish 4basebio as the partner of choice for companies developing next-generation therapeutics and vaccines.”
Wolosin commented that 4basebio's proprietary synthetic DNA platform addresses “critical limitations” of traditional plasmid-based systems.
“I have enjoyed working with the talented team at 4basebio to accelerate partnerships with innovators in gene therapy, mRNA therapeutics, and next-generation vaccines.
“The market opportunity is substantial, and we are uniquely positioned to capture it.”
To support its expanding commercial operations, 4basebio also promoted James Vang to vice-president of business development and Jennifer Gelman to vice-president of marketing.
At 1207 GMT, shares in 4basebio were flat at 580p.
Reporting by Josh White for Sharecast.com.